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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects (benefits and harms) of whole-body cryotherapy (cold air exposure) for preventing and treating muscle soreness
after exercise in adults.
B A C K G R O U N D
Elite-level athletic participation necessitates recovery from many
physiological stressors, including fatigue to the musculoskeletal,
nervous andmetabolic systems (Nédélec 2013). Athletic participa-
tion may also result in exercise-induced muscle damage (EIMD),
which may lead to delayed-onset muscle soreness (DOMS) and
decrements in subsequent performance (Howatson 2008). Various
therapeutic modalities of recovery are currently used by athletes
in an attempt to offset the negative effects of strenuous exercise
(Bieuzen 2013; Bleakley 2012; Nédélec 2013).
Description of the condition
DOMS is a broad term used to describe themuscular pain, tender-
ness and stiffness experienced after high-intensity, eccentric (when
the muscle is forcibly stretched when active) or unaccustomed ex-
ercise (Cheung 2003; Ebbeling 1989; Howatson 2008; Newham
1987). Clinically associated with EIMD, DOMS is proposed to
result frommechanical disturbances of the muscle membrane that
evoke secondary inflammation, swelling and free radical prolifera-
tion (Connolly 2003). These events typically peak 24 to 96 hours
post exercise (Cheung 2003) and may reduce physical capacity
via alterations in muscle length, maximal force and range of mo-
tion (Prasartwuth 2006; Saxton 1995). Although damage to the
exercised musculature is linked to the biochemical expression of
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intracellular enzymes, compensatory neuromuscular recruitment
patterns may contribute both central and peripheral factors to
DOMS aetiology (Byrne 2004).
Symptoms associated with DOMS typically dissipate within five
to seven days post exercise with adequate rest (Cheung 2003).Nev-
ertheless, various interventions have been advocated to prevent or
treat, or both prevent and treat, EIMD and associated DOMS, in-
cluding cool-down, stretching, nutritional supplements, massage,
hydrotherapy, compression, electrotherapy and non-steroidal anti-
inflammatorymedications (Bieuzen 2013; Bleakley 2012;Herbert
2011). Despite their widespread popularity (Nédélec 2013), em-
pirical support for the use of these interventions for DOMS re-
mains tenuous (Bleakley 2012; Herbert 2011).
Description of the intervention
Whole-body cryotherapy (WBC) is increasingly used in sports
medicine as treatment formuscle soreness after exercise. This treat-
ment involves exposing individuals to extremely cold dry air (be-
low -100°C) for two to four minutes. To achieve the subzero tem-
peratures required for WBC, two methods are typically used: liq-
uid nitrogen and refrigerated cold air. During these exposures, in-
dividuals wear minimal clothing, which usually consists of shorts
for males and shorts and a crop top for females. Gloves, a woollen
headband covering the ears, and a nose and mouth mask, in ad-
dition to dry shoes and socks, are commonly worn to reduce the
risk of cold-related injury.
The first WBC chamber was built in Japan in the late 1970s, but
WBC was not introduced to Europe until the 1980s, and has only
been used in the USA and Australia in the past decade (Miller
2012). The treatment was initially intended for use in a clinical
setting to treat patients with conditions such as multiple sclerosis
(Miller 2012) and rheumatoid arthritis (Hirvonen 2006; Metzger
2000); however, elite athletes have recently reported using the
treatment to alleviateDOMSafter exercise (Costello2012a; Fonda
2013; Hausswirth 2011; Pournot 2011; Ziemann 2012). WBC is
commonly employed shortly (within 0 to 24 hours) after exercise,
and the treatment is often repeated on the same day (Costello
2012a) or over several days (Lubkowska 2012; Ziemann 2012).
Recently, recreational athletes have started to emulate elite athletes
in using the treatment after exercise.
How the intervention might work
Reductions in muscle and skin tissue temperature after WBC ex-
posure (Costello 2012b; Costello 2012c; Costello 2013)may stim-
ulate cutaneous receptors and excite the sympathetic adrenergic
fibres, causing constriction of local arterioles and venules (Savic
2013). Consequently, WBC may be effective in relieving sore-
ness through reduced muscle metabolism, receptor sensitivity and
nerve conduction velocity. In addition, both Bleakley 2012 and
Cochrane 2004 describe the potential psychological benefits of us-
ing other modalities of cold exposure (e.g. cold water immersion)
to reduce the subjective feeling of DOMS following exercise.
Although the research examining WBC is typically limited in
terms of quality and statistical power (Costello 2012a; Costello
2012b), some studies have described a reduction in creatine ki-
nase activity after training (Wozniak 2007), increases in parasym-
pathetic activation (Hausswirth 2013) and an increase in anti-
inflammatory cytokines (proteins that serve to regulate the in-
flammatory response) (Lubkowska 2010; Lubkowska 2011) after
WBC exposure. A reduction in the severity of muscle damage af-
ter exercise and an increase in anti-inflammatory cytokines post-
treatment may help to reduce both the initial damage and the
secondary inflammatory damage associated with EIMD. How-
ever, from a mechanistic perspective, very little is known about
the physiological and biochemical rationale for using WBC in the
management of DOMS.
Using the approach described by Anderson 2011, we developed a
logic model to capture the wide range of potential effects of WBC
exposure (Figure 1). This model is divided into two sections: (1)
potential recovery benefits and (2) potential adverse effects. Miss-
ing from this model is any appraisal of the logistical, environmen-
tal and financial costs associated with WBC.
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Figure 1. Logic Model describing the potential benefits and adverse effects of whole-body cryotherapy
Why it is important to do this review
This review aims to examine the effects, both beneficial and harm-
ful, of WBC used for the purpose of preventing or treating muscle
soreness after exercise. Currently, no guidelines for a clinically ef-
fective or safe WBC protocol are available. Because of the extreme
temperatures employed during WBC, the potential for short- and
long-term adverse effects needs to be elucidated. A systematic re-
view of the evidence is also important because of the increasing
use of WBC by elite and recreational athletes and the potential
for long-term use throughout a sporting career in an attempt to
alleviate DOMS.
O B J E C T I V E S
To assess the effects (benefits and harms) of whole-body cryother-
apy (cold air exposure) for preventing and treating muscle soreness
after exercise in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised and quasi-randomised (method of
allocating participants to a treatment that is not strictly random,
e.g. by date of birth) controlled clinical trials evaluating WBC
for prevention and treatment of muscle soreness after exercise in
adults.
Types of participants
No restrictions will be placed on gender or on type or level of
exercise. All field- and laboratory-based (including eccentric) ex-
ercise modalities will be included. Studies focusing on children
(< 18 years of age) or injured participants will be excluded. We
anticipate that people with vascular problems, such as Raynaud’s
disease, who are contraindicated for cryotherapy, will be excluded
from trials.
Types of interventions
At least one group in the trial will comprise participants treated
with whole-body cryotherapy before or after exercise.WBCwill be
defined as exposure of the body (trunk, arms and legs) to extremely
cold dry air (below -100°C). These exposures can be administered
as a once-off treatment, or they can be repeated several times on
the same days or over several days.
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Consistent with the logic model included in this protocol, com-
parisons can be made with any other form of intervention de-
signed to prevent or treat DOMS, including, but not limited to,
passive interventions (rest, no treatment or placebo treatment),
cold water immersion (immersion in water colder than 15°C),
warm water immersion (immersion in water warmer than 15°C),
contrast water immersion (alternating hot and cold water immer-
sion), cool-down, stretching, massage and compression garments.
Studies comparing different durations or dosages of WBC will be
included. Trials in which the same WBC protocol is used in both
arms as a co-intervention will not be included. Comparisons with
pharmacological interventions will be excluded.
Types of outcome measures
Primary outcomes
• Muscle soreness (e.g. pain measured with the use of visual
analogue scales and algometer data)
• Subjective recovery (return to previous activities without
signs or symptoms)
• Immediate or long-term complications or adverse effects
(e.g. frost bite, adverse cardiac or vascular events, musculoskeletal
injury)
Secondary outcomes
• Muscle strength and power (muscle contractile properties)
• Objective test of function and performance (e.g. hop test)
Resource use
We will collect cost and resource data, including cost of the inter-
vention and cost of time off work or professional sports activity.
Timing of outcome assessment
We plan to collect data at the following follow-up times: immedi-
ately and 24, 48, 72, 96 andmore than 96 hours post intervention.
These are typical follow-up times for studies assessing treatment
for DOMS.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Bone, Joint and Muscle Trauma
Group SpecialisedRegister, theCochraneCentral Register of Con-
trolled Trials (to present), MEDLINE (1946 to present), EM-
BASE (1974 to present), Cumulative Index to Nursing and Allied
Health (CINAHL) (1982 to present), British Nursing Index and
archive (BNI) (1985 to present) and the Physiotherapy Evidence
Database (PEDro) (1929 to present).
In MEDLINE, the subject-specific search will be combined with
the sensitivity- and precision-maximising version of the Cochrane
Highly Sensitive Search Strategy for identifying randomised trials
(Lefebvre 2011). This strategy will be modified for use in other
databases (see Appendix 1 for the MEDLINE search strategy).
We will also search Current Controlled Trials and the WHO
International Clinical Trials Registry Platform for ongoing and
recently completed trials.
We will apply no language restrictions.
Searching other resources
The reference lists of relevant articles will be searched in addition
to the table of contents of the following journals not registered as
being handsearched by the Cochrane Collaboration.
• (Australian) Journal of Science and Medicine in Sport (1998
to present).
• British Journal of Sports Medicine (1964 to present).
• Clinical Journal of Sport Medicine (1991 to present).
• International Journal of Sports Medicine (2005 to present).
• Journal of Applied Physiology (1948 to present).
• Journal of Sports Medicine and Physical Fitness (1998 to
present).
• Journal of Sports Sciences (1985 to 1987; 1990 to 1991;
1994; 1996; 2000 to present).
• Medicine and Science in Sports and Exercise (1980 to
present).
• Physical Therapy in Sport (2000 to 2002; 2007 to present).
We will also search the conference proceedings of the following
organisations.
• American College of Sports Medicine (1986 to present) (in
Medicine and Science in Sports and Exercise).
• American Physical Therapy Association (1980 to present)
(in Physical Therapy).
• British Association of Sport and Exercise Medicine
(BASEM) (1964 to present) (in British Journal of Sports
Medicine).
• British Association of Sport and Exercise Sciences (BASES)
(1964 to present) (in Journal of Sports Sciences).
• World Confederation for Physical Therapy (2003, 2007,
2011) (CD-ROM).
Data collection and analysis
Selection of studies
Two review authors (JTC, GMM) will independently select trials
for inclusion. First, we will screen titles and abstracts of publica-
tions obtained by the search strategy and will remove only those
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that are obviously outside the scope of the review. We will be over-
inclusive at this stage and will seek the full text for any papers
that might meet the review inclusion criteria. We will aim to link
together multiple publications and reports of the same study. The
same two review authors will then independently select trials us-
ing a standardised form to record their choices. We will not be
blinded during this process with respect to authors’ names, journal
or date of publication. When possible, translation of non-English
language studies will be undertaken. Primary authors will be con-
tacted when necessary to ask for clarification of study characteris-
tics. Disagreement between the review authors will be resolved by
consensus or by third party adjudication (CB, PRAB, IBS).
Data extraction and management
Two review authors (JTC, CB) will use a customised form to inde-
pendently extract relevant data on methodology, eligibility crite-
ria, interventions (including detailed characteristics of the exercise
protocols and the whole-body cryotherapy protocol employed),
comparisons and outcome measures. Details of the characteristics
of included participants such as training status, age, sex and health
status will also be recorded. When available, we will also extract
data on participant subgroups, including any equity considera-
tions such as ethnicity and socioeconomic status. Any included
study written by one of the current review authors will be reviewed
by review authors who did not participate in the original study.
Any disagreement will be resolved by consensus or by third party
adjudication (GMM, PRAB). Primary authors will be contacted
to clarify any omitted data or study characteristics. For intention-
to-treat analysis, data will be extracted according to the original
allocation groups, and losses to follow-up will be noted when pos-
sible.
Assessment of risk of bias in included studies
Two review authors (JTC, CB) will independently assess risk of
bias using the tool described (and the criteria outlined) in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). To minimise bias in the interpretation of this scale, two
review authors (JTC, CB) will initially assess a small sample of
unrelated studies (not included in the current review); disparities
in risk of bias judgements will be reviewed and discussed before
any of the included studies is evaluated.
Each study will be graded for risk of bias in each of the follow-
ing domains: sequence generation, allocation concealment, blind-
ing (participants and interventionproviders; outcome assessment),
incomplete outcome data and selective outcome reporting. Two
other sources of bias will be considered on the basis of the follow-
ing questions: (1) Was the exercise protocol clear and consistent
between groups? (2) Were co-interventions used, and if so, were
they standardised across groups? For each study, the information
pertaining to each of the domains will be described as reported in
the published study report (or, if appropriate, based on informa-
tion from related protocols or published comments or after dis-
cussion with the relevant authors) and the associated risk of bias
judged by the review authors. Studies will be assigned ’high risk’,
’low risk’ or ’unclear risk’ when there is uncertainty or when in-
formation is insufficient to allow review authors to make a judge-
ment. Disagreements between review authors regarding the risk of
bias assessment will be resolved by consensus.
Measures of treatment effect
For each study, risk ratios and 95% confidence intervals will be
calculated for dichotomous outcomes, and mean differences and
95% confidence intervals for continuous outcomes. For contin-
uous outcomes that are pooled on different scales, standardised
mean differences will be used. When possible, follow-up scores
will be used in preference to change scores.
Unit of analysis issues
If trials include data from a cluster-randomised study design, the
data will be adjusted for clustering when possible. It is possible
that studies will include repeated observations of the same out-
come; consequently we will extract data at clinically relevant time
points. When available, the following time points will be included:
immediately after the exercise, immediately after the intervention
and then at 24-hour intervals (0 to 24 hours, 25 to 48 hours, 49
to 72 hours, 73 to 96 hours and over 96 hours).
Dealing with missing data
In cases where data are missing, we will consider why they are
missing. Whenever possible, we will contact study authors to re-
quest missing data or to ask for an explanation as to why data are
missing. Unless missing standard deviations can be derived from
confidence intervals, standard errors or exact P values, we will not
assume or impute values for these in order to present results in the
analyses.
Assessment of heterogeneity
Assessment of heterogeneity between comparable trials will be
evaluated visually with the use of forest plots, as well as Chi² tests
and I² statistics. The level of significance for theChi² test will be set
at P = 0.1 (Deeks 2011): a P value for Chi² < 0.1 will be considered
to indicate statistically significant heterogeneity between studies.
Values of I² will be interpreted as follows: 0% to 40%might not be
important; 30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity; and 75%
to 100% may represent considerable heterogeneity.
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Assessment of reporting biases
We will be vigilant in watching for duplicate publications of the
same studies. Funnel plots of the effect estimates against standard
error (on a reversed scale) will be created using Review Manager
(RevMan 2011); these will be used to assess reporting bias when
10 or more trials are included in a comparison. Standard errors
will be plotted on the vertical scale. Effect estimates will therefore
be plotted on the horizontal scale, with continuous data repre-
sented as standardised mean differences, and dichotomous data
represented as risk ratios on a logarithmic scale.
Data synthesis
When considered appropriate, results of comparable groups of
trials will be pooled using both fixed-effect and random-effects
models. The choice of themodel to report will be guided by careful
consideration of the extent of heterogeneity and whether it can be
explained, in addition to other factors, such as the number and
size of included studies. Ninety-five per cent confidence intervals
will be used throughout. We will consider not pooling data when
considerable heterogeneity (I² > 75%) that cannot be explained
by the diversity of methodological or clinical features is observed
among trials. When it is inappropriate to pool data, we will still
present trial data in the analyses or tables for illustrative purposes
and will report them in the text.
Subgroup analysis and investigation of heterogeneity
When data allow, we intend to perform the following subgroup
analyses.
• Gender (male versus female)
• Exposure dose (single versus repeated exposures; short
versus long exposure durations)
• Exercise type (normal sporting activities and laboratory-
induced DOMS)
• Training status (elite versus recreational)
We have chosen these subgroup analyses because gender, type of
athletic activity and training status may impact the severity of
DOMS experienced after exercise (Howatson 2008; McGinley
2009). In particular, DOMS may be augmented in untrained
males after eccentric exercise when compared with trained females
performing concentric exercise. Moreover, reductions in tissue
temperature may be more pronounced after repeated, or longer,
WBC exposures (Costello 2012c).We will investigate whether the
results of subgroups are significantly different by inspecting the
overlap of confidence intervals and by performing the test for de-
termining subgroup differences that is available in Review Man-
ager (RevMan 2011).
Sensitivity analysis
If some of the included trials are at high risk of bias for one or more
domains, wewill perform sensitivity analysis to determine whether
inclusion of such trials significantly influences the effect size. We
will consider trials at high risk of bias in sensitivity analysis if allo-
cation concealment is unclear or at high risk of bias, or if attrition
is greater than 20%. We will also carry out sensitivity analysis to
explore the effects of using fixed-effect or random-effects analyses
for outcomes with statistical heterogeneity and the effects of any
assumptions made, such as the value of the intracluster correlation
coefficient used for cluster-randomised trials.
Summary of findings table
We will prepare a ’Summary of findings’ table for each of the main
comparisons using the GRADE profiler (Schünemann 2011). We
will summarise the quality of evidence by applying the principles
of the GRADE framework and following the recommendations
and worksheets of Cochrane Effective Practice and Organisation
of Care Group for creating ’Summary of findings’ tables (EPOC
2011). Thus, we will use four levels of quality (high, moderate,
low and very low) to describe the body of evidence.
A C K N OW L E D G E M E N T S
We would like to thank Dr Joanne Elliott for her help with the
search strategy and Mrs Lindsey Elstub for her help during the
editorial process. We are grateful to Dr Nigel Hanchard and Mr
Matthew Wright for their helpful feedback on the protocol.
6Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Anderson 2011
Anderson LM, Petticrew M, Rehfuess E, Armstrong R,
Ueffing E, Baker P, et al.Using logic models to capture
complexity in systematic reviews. Research Synthesis 2011;2
(1):33–42.
Bieuzen 2013
Bieuzen F, Bleakley CM, Costello JT. Contrast water
therapy and exercise induced muscle damage: a systematic
review and meta-analysis. PLoS ONE 2013;8(4):e62356.
[DOI: 10.1371/journal.pone.0062356]
Bleakley 2012
Bleakley C, McDonough S, Gardner E, Baxter GD,
Hopkins JT, Davison GW. Cold-water immersion
(cryotherapy) for preventing and treating muscle soreness
after exercise. Cochrane Database of Systematic Reviews 2012,
Issue 2. [DOI: 10.1002/14651858.CD008262.pub2]
Byrne 2004
Byrne C, Twist C, Eston R. Neuromuscular function after
exercise-induced muscle damage. Sports Medicine 2004;34
(1):49–69.
Cheung 2003
Cheung K, Hume P, Maxwell L. Delayed onset muscle
soreness: treatment strategies and performance factors.
Sports Medicine 2003;33(2):145–64.
Cochrane 2004
Cochrane DJ. Alternating hot and cold water immersion for
athlete recovery: a review. Physical Therapy in Sport 2004;5
(1):26–32.
Connolly 2003
Connolly DA, Sayers SE, McHugh MP. Treatment and
prevention of delayed onset muscle soreness. Journal of
Strength and Conditioning Research 2003;17(1):197–208.
Costello 2012a
Costello JT, Algar LA, Donnelly AE. Effects of whole body
cryotherapy (−110°C) on proprioception and indices of
muscle damage. Scandinavian Journal of Medicine and
Science in Sports 2012;22(2):190–8.
Costello 2012b
Costello JT, Culligan K, Selfe J, Donnelly AE. Muscle,
skin and core temperature after −110°C cold air and 8°C
water treatment. PLoS ONE 2012;7(11):e48190. [DOI:
10.1371/journal.pone.0048190]
Costello 2012c
Costello JT, McInerney CD, Bleakley CM, Selfe J,
Donnelly AE. The use of thermal imaging in assessing skin
temperature following cryotherapy: a review. Journal of
Thermal Biology 2012;37(2):103–10.
Costello 2013
Costello JT, Donnelly AE, Karki A, Selfe J. Effects of whole
body cryotherapy and cold water immersion on knee skin
temperature. International Journal of Sports Medicine 2013
[Epub ahead of print]. [DOI: 10.1055/s-0033-1343410]
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Green S editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Ebbeling 1989
Ebbeling C, Clarkson P. Exercise-induced muscle damage
and adaptation. Sports Medicine 1989;7(4):207–34.
EPOC 2011
EPOC. Worksheets for preparing a summary of findings
using GRADE, 2011. http://epocoslo.cochrane.org/
sites/epocoslo.cochrane.org/files/uploads/
EPOC%20worksheets%20for%20preparing%20a%20summary%20of%20findings%20using%20GRADE˙0.doc
Vol. (accessed 23 May 2013).
Fonda 2013
Fonda B, Sarabon N. Effects of whole-body cryotherapy
on recovery after hamstring damaging exercise: a crossover
study. Scandinavian Journal of Medicine and Science in
Sports 2013 Apr 25 [Epub ahead of print]. [DOI: doi:
10.1111/sms.12074]
Hausswirth 2011
Hausswirth C, Louis J, Bieuzen F, Pournot H, Fournier
J, Filliard JR. Effects of whole-body cryotherapy vs.
far-infrared vs. passive modalities on recovery from
exercise-induced muscle damage in highly-trained
runners. PLoS ONE 2011;6(12):e27749. [DOI: 10.1371/
journal.pone.0027749]
Hausswirth 2013
Hausswirth C, Schaal K, Le Meur Y, Bieuzen F,
Filliard J-R, Volondat M, et al.Parasympathetic
activity and blood catecholamine responses following a
single partial-body cryostimulation and a whole-body
cryostimulation. PLoS ONE 2013;8(8):e72658. doi:
10.1371/journal.pone.0072658.
Herbert 2011
Herbert RD, de Noronha M, Kamper SJ. Stretching to
prevent or reduce muscle soreness after exercise. Cochrane
Database of Systematic Reviews 2011, Issue 7. [DOI:
10.1002/14651858.CD004577.pub3]
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions. Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Hirvonen 2006
Hirvonen H, Mikkelsson M, Kautiainen H, Pohjolainen
TH, Leirisalo-Repo M. Effectiveness of different
cryotherapies on pain and disease activity in active
rheumatoid arthritis: a randomised single blinded
7Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
controlled trial. Clinical and Experimental Rheumatology
2006;24(3):295–301.
Howatson 2008
Howatson G, van Someren KA. The prevention and
treatment of exercise induced muscle damage. Sports
Medicine 2008;38(6):483–503.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 [updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Lubkowska 2010
Lubkowska A, Szygula Z, Klimek A, Torii M. Do sessions of
cryostimulation have influence on white blood cell count,
level of IL6 and total oxidative and antioxidative status in
healthy men?. European Journal of Applied Physiology 2010;
109(2):67–72.
Lubkowska 2011
Lubkowska A, Szygu a Z, Chlubek D, Banfi G. The effect
of prolonged whole-body cryostimulation treatment with
different amounts of sessions on chosen pro- and anti-
inflammatory cytokine levels in healthy men. Scandinavian
Journal of Clinical and Laboratory Investigation 2011;71(5):
419–25.
Lubkowska 2012
Lubkowska A, Do gowska B, Szygu a Z. Whole-
body cryostimulation-potential beneficial treatment for
improving antioxidant capacity in healthy men-significance
of the number of sessions. PLoS ONE 2012;7(10):e46352.
[DOI: 10.1371/journal.pone.0046352]
McGinley 2009
McGinley C, Shafat A, Donnelly AE. Does antioxidant
vitamin supplementation protect against muscle damage?.
Sports Medicine 2009;39(12):1011–32.
Metzger 2000
Metzger D, Zwingmann C, Protz W, Jackel WH. Whole-
body cryotherapy in rehabilitation of patients with
rheumatoid diseases-pilot study. Rehabilitation 2000;39(2):
93–100.
Miller 2012
Miller E, Markiewicz L, Saluk J, Majsterek I. Effect of
short-term cryostimulation on antioxidative status and its
clinical applications in humans. European Journal of Applied
Physiology 2012;112(5):1645–52.
Newham 1987
Newham DJ, Jones DA, Clarkson PM. Repeated high-
force eccentric exercise: effects on muscle pain and damage.
Journal of Applied Physiology 1987;63(4):1381–6.
Nédélec 2013
Nédélec M, McCall A, Carling C, Legall F, Berthoin S,
Dupont G. Recovery in soccer: part II-recovery strategies.
Sports Medicine 2013;43(1):9–22.
Pournot 2011
Pournot H, Bieuzen F, Louis J, Fillard JR, Barbiche E,
Hausswirth C. Time-course of changes in inflammatory
response after whole-body cryotherapy multi exposures
following severe exercise. PLoS ONE 2011;6(7):e22748.
[DOI: doi:10.1371/journal.pone.0022748]
Prasartwuth 2006
Prasartwuth O, Allen TJ, Butler JE, Gandevia SC, Taylor
JL. Length-dependent changes in voluntary activation,
maximum voluntary torque and twitch responses after
eccentric damage in humans. Journal of Physiology 2006;
571(1):243–52.
RevMan 2011
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.1. The Nordic Cochrane
Centre, The Cochrane Collaboration, 2011.
Savic 2013
Savic M, Fonda B, Sarabona N. Actual temperature during
and thermal response after whole-body cryotherapy in cryo-
cabin. Journal of Thermal Biology 2013;38(4):186–91.
Saxton 1995
Saxton JM, Clarkson PM, James R, Miles M, Westerfer
M, Clark S, et al.Neuromuscular dysfunction following
eccentric exercise. Medicine and Science in Sports and
Exercise 1995;27(8):1185–93.
Schünemann 2011
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT,
Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results
and drawing conclusions. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Wozniak 2007
Wozniak A, Wozniak B, Drewa G, Mila-Kierzenkowska
C, Rakowski A. The effect of whole-body cryostimulation
on lysosomal enzyme activity in kayakers during training.
European Journal of Applied Physiology 2007;100(2):137–42.
Ziemann 2012
Ziemann E, Olek RA, Kujach S, Grzywacz T, Antosiewicz
J, Garsztka T, et al.Five-day whole-body cryostimulation,
blood inflammatory markers, and performance in high-
ranking professional tennis players. Journal of Athletic
Training 2012;47(6):664–72.
∗ Indicates the major publication for the study
8Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1 Cryotherapy/
2 Hypothermia, Induced/
3 cryotherapy.tw.
4 cryostimulation.tw.
5 cooling.tw.
6 ((cold or cool*) adj3 (air or treat* or chamber*)).tw.
7 “liquid nitrogen”.tw.
8 (low adj2 temp*).tw.
9 or/1-8
10 Exercise/
11 Sports/
12 Muscle, Skeletal/
13 Athletic Injuries/
14 Soft Tissue Injuries/
15 exp Creatine Kinase/
16 Physical Exertion/
17 Muscle Fatigue/
18 Muscle Cramp/ or Spasm/ or Muscle Rigidity/ or “Sprains and Strains”/ or Muscle Weakness/
19 (sore$ adj3 musc$).tw.
20 DOMS.tw.
21 (exercise induced and (muscle$ adj2 (damage$ or injur$))).tw.
22 Lactic Acid/
23 (lactate$ or lactic).tw.
24 or/10-23
25 9 and 24
26 Randomized controlled trial.pt.
27 Controlled clinical trial.pt.
28 randomized.ab.
29 placebo.ab.
30 Clinical Trials as Topic/
31 randomly.ab.
32 trial.ti.
33 26 or 27 or 28 or 29 or 30 or 31 or 32
34 exp Animals/ not Humans/
35 33 not 34
36 25 and 35
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